Cellectar Biosciences, Inc. (CLRB) News
Follow Cellectar Biosciences, Inc. (CLRB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Cellectar Biosciences Q3'26 Earnings Preview: EPS Estimated at $(0.56)
Cellectar Biosciences is expected to report Q3'26 results on November 10 before the market opens. Revenue is estimated at $0, with EPS expected at $(0.56).
EQUITY | Nov 09, 2026, 12:02 PM UTC
M
Cellectar Biosciences to Report Third-Quarter Results November 10
Cellectar Biosciences plans to report third-quarter financial results and host a conference call on November 10, 2026.
EQUITY | Nov 02, 2026, 01:04 PM UTC
M
Cellectar Biosciences Q3'26 Results Due October 29; EPS Estimate Is (0.56) USD
The company is expected to report Q3'26 results on October 29. Revenue is estimated at 0 USD, with EPS expected at (0.56) USD; the release time is not specified.
EQUITY | Oct 28, 2026, 11:05 AM UTC
L
Cellectar Biosciences, Inc. (CLRB) Posts 79% Major Response in WM Subset
Cellectar Biosciences reported a 79.2% major response rate, 87.5% overall response, and duration exceeding 16 months in a Phase 2 CLOVER WaM subset treated immediately post-BTKi, and plans a Phase 3 confirmatory trial wi
CENTRAL_BANK | Sep 29, 2026, 11:33 AM UTC
L
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi TherapyData Furth
CENTRAL_BANK | Sep 29, 2026, 11:33 AM UTC